Zobrazeno 1 - 10
of 4 030
pro vyhledávání: '"PD-L1 EXPRESSION"'
Autor:
Sneha Burela, Mengni He, Ioannis P. Trontzas, Niki Gavrielatou, Kurt A. Schalper, Solomon Langermann, Dallas B. Flies, David L. Rimm, Thazin N. Aung
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Basal Cell Adhesion Molecule (BCAM), a receptor for laminin subunit α5, plays a crucial role in the pathogenesis of various malignancies. Notably, evidence of hypermethylation at multiple immune checkpoints in patients with low BCAM express
Externí odkaz:
https://doaj.org/article/e06f9eb926d740f08bba636b5ace8940
Autor:
Yu Fan, Tao Dai, Dahong Zhang, Hongqian Guo, Fangjian Zhou, Benkang Shi, Shaogang Wang, Zhigang Ji, Chunxi Wang, Xudong Yao, Qiang Wei, Nanhui Chen, Jinchun Xing, Jinjian Yang, Chuize Kong, Jian Huang, Dingwei Ye, Liqun Zhou
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Data on prevalence of programmed death ligand-1 (PD-L1) expression and its correlation with tumor biomarkers in Chinese patients with muscle-invasive urothelial bladder cancer (MIUBC) are scarce. We investigated the prevalence of PD-L1 expre
Externí odkaz:
https://doaj.org/article/72a42ffa953e481b88559dbe7d08912f
Autor:
Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, Yun-Gyoo Lee, Su-Jin Shin, Beung-Chul Ahn, Sung Sook Lee, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the efficacy and safety of spartalizumab in patients with refractory esophageal s
Externí odkaz:
https://doaj.org/article/7b1070c787db4a9e95ccef4e55841573
Autor:
Hejing Bao, Jiani Zhang, Yuhuan Wang, Zhiting Chen, Xi Luo, Ting Li, Haoran Su, Hehong Bao, Xiaolong Cao, Liping Lin
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
We report a case of an advanced non-small cell lung cancer (NSCLC) patient with brain metastasis, RET fusion, and high expression of programmed death ligand 1 (PD-L1) at initial treatment. After receiving radiotherapy for the brain metastasis, the pa
Externí odkaz:
https://doaj.org/article/220e0729461b489eab3a0b8454876372
Autor:
Brittany File, Anjali Hari
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101484- (2024)
Introduction: Pembrolizumab is an immunotherapy approved for use in patients with a combined positive score (CPS) greater than one with recurrent cervical cancer. In clinical practice, the CPS score is not typically analyzed in both primary and metas
Externí odkaz:
https://doaj.org/article/826fcc0e81174321b1bfc28a233921bf
Autor:
Huayi Li, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ruifang An, Hong Zheng, Pengpeng Qu, Li Wang, Qi Zhou, Danbo Wang, Ge Lou, Jing Wang, Ke Wang, Beihua Kong, Xing Xie, Rutie Yin, John Low, Abdul Malik Rozita, Lim Chun Sen, Yong Chee Meng, Kho Swee Kiong, Jihong Liu, Zhiqing Liang, Weiguo Lv, Yaping Zhu, Weiguo Hu, Wei Sun, Jingya Su, Qiqi Wang, Rongyu Zang, Ding Ma, Qinglei Gao
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensiti
Externí odkaz:
https://doaj.org/article/f5e3af1247dd40f9aa8344da62322e0a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo assess the effectiveness and tolerability of both PD-1 and PD-L1 inhibitors in advanced cervical cancer (CC), focusing on varying PD-L1 levels.MethodsA comprehensive exploration was carried out on EMBASE, PubMed, Cochrane Library database
Externí odkaz:
https://doaj.org/article/7d5fe4a45db04564a6f81d79662069fe
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
Autor:
Xu Yang, Baofeng Lian, Nan Zhang, Junyu Long, Yiran Li, Jingnan Xue, Xiangqi Chen, Yunchao Wang, Yanyu Wang, Ziyu Xun, Mingjian Piao, Chenpei Zhu, Shanshan Wang, Huishan Sun, Zhijian Song, Leilei Lu, Xiaowei Dong, Aodi Wang, Wenjin Liu, Jie Pan, Xiaorong Hou, Mei Guan, Li Huo, Jie Shi, Haohai Zhang, Jinxue Zhou, Zhenhui Lu, Yilei Mao, Xinting Sang, Liqun Wu, Xiaobo Yang, Kai Wang, Haitao Zhao
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Microsatellite instability-high (MSI-H) is a unique genomic status in many cancers. However, its role in the genomic features and immunotherapy in cholangiocarcinoma (CCA) is unclear. This study aimed to systematically investigate
Externí odkaz:
https://doaj.org/article/e96e78be7cfb426197e9dec8e4c18944
Autor:
Jianqiu Kong, Yitong Zou, Hua Zhou, Yi Huang, Ying Lin, Shuogui Fang, Zhijian Chen, Junjiong Zheng, Yaqiang Huang, Zefeng Shen, Weibin Xie, Xinxiang Fan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe therapeutic effectiveness of immune checkpoint inhibitors (ICIs) in bladder cancer varies among individuals. Identifying reliable predictors of response to these therapies is crucial for optimizing patient outcomes.MethodsThis retrospec
Externí odkaz:
https://doaj.org/article/f025e47d0d24446e85fa16abb4c9b5ed
Autor:
Tomáš Blažek, Marek Petráš, Pavel Hurník, Petr Matoušek, Lukáš Knybel, Zuzana Zděblová Čermáková, Jan Štembírek, Jakub Cvek, Renata Soumarová
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionIn the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment.MethodsTo e
Externí odkaz:
https://doaj.org/article/f532011d5f7f4bf0866b6d48cc9402f5